SEC Company Response from Aprea Therapeutics, Inc. (APRE) (CIK 0001781983) (APRE) — Sep 30, 2019
Aprea Therapeutics, Inc. (APRE) (CIK 0001781983)
Date: Sept. 30, 2019 · CIK: 0001781983 · Accession: 0001104659-19-052033
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233662
Letter
September 30, 2019
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Sonia Bednarowski
Dietrich King
Keira Nakada
Kevin Vaughn
Re: Acceleration Request for Aprea Therapeutics, Inc.
Registration Statement on Form S-1 (File No. 333-233662)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-1, Registration Number 333-233662 (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:00 P.M., Eastern Time or as soon thereafter as practicable, on October 2, 2019, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.
[Signature Page Immediately Follows]
We would appreciated it if, as soon as the Registration Statement is declared effective, you would so inform Istvan A. Hajdu of Sidley Austin LLP at (212) 839-5651.
Very truly yours,
/s/ Christian S. Schade
Show Raw Text
CORRESP 1 filename1.htm September 30, 2019 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Sonia Bednarowski Dietrich King Keira Nakada Kevin Vaughn Re: Acceleration Request for Aprea Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-233662) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-1, Registration Number 333-233662 (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:00 P.M., Eastern Time or as soon thereafter as practicable, on October 2, 2019, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission. [Signature Page Immediately Follows] We would appreciated it if, as soon as the Registration Statement is declared effective, you would so inform Istvan A. Hajdu of Sidley Austin LLP at (212) 839-5651. Very truly yours, /s/ Christian S. Schade Christian S. Schade Chief Executive Officer cc: Scott M. Coiante, Aprea Therapeutics, Inc. Geoffrey W. Levin, Sidley Austin LLP Samir A. Gandhi, Sidley Austin LLP Istvan A. Hajdu, Sidley Austin LLP Richard D. Truesdell, Jr., Davis Polk & Wardwell LLP Derek Dostal, Davis Polk & Wardwell LLP